Truist Securities Reiterates Buy on Bristol-Myers Squibb, Maintains $84 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Gregg Gilbert has reiterated a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY) and maintained an $84 price target.
June 28, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a 'Buy' rating on Bristol-Myers Squibb and maintained an $84 price target, potentially indicating a positive outlook for the company's stock.
The reiteration of a 'Buy' rating by Truist Securities indicates their continued confidence in Bristol-Myers Squibb's performance. The maintained price target of $84 suggests they believe the stock is still undervalued, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100